Citation Impact
Citing Papers
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
2010 StandoutNobel
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice
2007 StandoutNobel
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer
2008
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
1999 StandoutNobel
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Efficient T Cell Activation via a Toll-Interleukin 1 Receptor-Independent Pathway
2006 StandoutNobel
The ubiquitin–proteasome pathway in thymocyte apoptosis: caspase-dependent processing of the deubiquitinating enzyme USP7 (HAUSP)
2002
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells
1998 StandoutNobel
Imaging in the era of molecular oncology
2008 StandoutNature
CTLA-4: new insights into its biological function and use in tumor immunotherapy
2002 StandoutNobel
A Genomic and Functional Inventory of Deubiquitinating Enzymes
2005 Standout
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
2007
Surface modification of neural recording electrodes with conducting polymer/biomolecule blends
2001
Iterative In Situ Click Chemistry Creates Antibody‐like Protein‐Capture Agents
2009 StandoutNobel
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Bystander elimination of antigen loss variants in established tumors
2004
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond
2003 Standout
T cells down-modulate peptide-MHC complexes on APCs in vivo
2001
An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence
2010 StandoutNobel
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
2003 StandoutNobel
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Gated supramolecular chemistry in hybrid mesoporous silica nanoarchitectures: controlled delivery and molecular transport in response to chemical, physical and biological stimuli
2015
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
2009 StandoutNobel
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+T cell responses
1999 StandoutNobel
Type I interferons produced by dendritic cells promote their phenotypic and functional activation
2002
Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells
2003
Dendritic cells with TGF-β1 differentiate naïve CD4+CD25−T cells into islet-protective Foxp3+regulatory T cells
2007 StandoutNobel
Functional differences between memory and naive CD8 T cells
1999
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
2004 StandoutNobel
Cucurbituril-Based Molecular Recognition
2015 Standout
Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses
2011 StandoutNobel
Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue
2001 StandoutScience
Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen.
2001
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
2004 StandoutNobel
Polymer Brushes via Surface-Initiated Controlled Radical Polymerization: Synthesis, Characterization, Properties, and Applications
2009 Standout
The Current Status of Heterocyclic Combinatorial Libraries
1997
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Identification of MHC Class II-Restricted Peptide Ligands, Including a Glutamic Acid Decarboxylase 65 Sequence, that Stimulate Diabetogenic T Cells from Transgenic BDC2.5 Nonobese Diabetic Mice
2001
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 StandoutScience
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
2006 StandoutNobel
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells
2000
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells
2000 StandoutNobel
CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes
2004 StandoutNobel
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
2011
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy
2001 StandoutNobel
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
2011 StandoutNobel
Tolerogenic Dendritic Cells
2003 StandoutNobel
The “One-Bead-One-Compound” Combinatorial Library Method
1997
Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells
2000
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
2005 StandoutNobel
Immunogenicity. I. Use of Peptide Libraries to Identify Epitopes That Activate Clonotypic CD4+ T Cells and Induce T Cell Responses to Native Peptide Ligands
1999
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells
1998 StandoutNobel
Works of Sandra Kienle being referenced
Modification of glassy carbon surfaces with synthetic laminin-derived peptides for nerve cell attachment and neurite growth
1998
Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL.
1996
Polymer‐Modified Mesoporous Silica Thin Films for Redox‐Mediated Selective Membrane Gating
2013
Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone.
1996
Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries.
1995